Masimo Corporation announced that its Board of Directors has nominated Christopher Chavez for election as a Class II Director at the Company?s 2024 Annual Meeting of Stockholders. Following Rolf Classon?s unexpected resignation from the Board on May 10, 2024, due to health issues, members of the Board contacted and considered several candidates with skills and experiences that would enhance the Board?s slate. Mr. Chavez brings more than 30 years of leadership experience in the medical device industry, including two past appointments as a public company CEO and many years as an independent public company director.

Separately, the Company extended its third settlement offer to Politan Capital Management, proposing that Mr. Chavez and Politan nominee William Jellison be added to the Board. The expansion of the Board to seven members, six of whom are independent, would avoid concerns of potential deadlock on the Board. Politan rejected the offer.

Prior to ANSI, Mr. Chavez spent 15 years at Johnson & Johnson, most recently as Vice President and General Manager of the Worldwide Infection Prevention Business. In addition to his board service at ANSI and TriVascular, Mr. Chavez previously served as an independent director at Endologix, Nuvectra Corp. and Advanced Medical Optics Inc., which was acquired by Abbott Laboratories in 2009.

He also served as Chair of the Medical Device Manufacturers Association and Chairman of the Dallas/Fort Worth Health Industry Council. Mr. Chavez received his MBA from the Harvard Business School and holds a bachelor?s degree in accounting from New Mexico State University.